IP Library Granted Patent US 9,834,787
Granted Patent B2
US 9,834,787 · App. 12/798,749 · Granted Dec 5, 2017

Targeted integration into stem cells

Inventors: Philip D. Gregory (Orinda, CA); Dirk Hockemeyer (Cambridge, MA); Michael C. Holmes (Oakland, CA); Rudolf Jaenisch (Cambridge, MA); Frank Soldner (Cambridge, MA); Fyodor Urnov (Point Richmond, CA); Shuyuan Yao (San Diego, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/86C12N9/22C12N2710/10343C12N2740/15043C12N2800/30C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,787
App. No.
12/798,749
Granted
Dec 5, 2017
Kind
B2
Abstract

Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells.

Claims (7)

1. An isolated pluripotent or multipotent stem cell comprising a transgene, wherein the transgene is integrated into an endogenous PITX3 or Factor IX gene of the stem cell using a pair of zinc finger nucleases that bind to and cleave the endogenous PITX3 or Factor IX gene, wherein the pair of zinc finger nucleases bind to paired target sites of SEQ ID NO:47 and SEQ ID NO:48 of the PITX3 gene, or paired target sites of SEQ ID NO:49 and SEQ ID NO:50 of the PITX3 gene, or to paired target sites of SEQ ID NO:51 and SEQ ID NO:56 of the Factor IX gene, and further wherein the pair of zinc finger nucleases cleaves the PITX3 or Factor IX gene within or between the paired target sites such that the transgene is integrated into the PITX3 or Factor IX gene.

2. The isolated stem cell of claim 1 , wherein the stem cell is selected from the group consisting of a hematopoietic stem cell, a mesenchymal stem cell, an embryonic stem cell, a neuronal stem cell, a muscle stem cell, a liver stem cell, a skin stem cell, and an induced pluripotent stem cell.

3. The isolated stem cell of claim 1 , wherein the stem cell is a mammalian stem cell.

4. The isolated stem cell of claim 3 , wherein the stem cell is a human induced pluripotent stem cell (hiPSC).

5. The isolated stem cell of claim 1 , wherein the transgene is flanked by recombinase sites.

6. The isolated stem cell of claim 1 , further comprising a sequence encoding a reporter construct.

7. A stem cell according to claim 1 , wherein the isolated transgene comprises a sequence encoding a lineage-specific or cell fate marker as shown in Table 1.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jun 17, 2021
From: WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 056615/0658 →
CHANGE OF NAME Recorded Sep 1, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 043749/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2010
From: GREGORY, PHILIP D.; HOLMES, MICHAEL C.; URNOV, FYODOR; YAO, SHUYUAN
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 024904/0409 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2010
From: HOCKEMEYER, DIRK; JAENISCH, RUDOLF; SOLDNER, FRANK
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 024904/0414 →
Continuity (3)
Provisional Application 61212265 · Apr 9, 2009
Provisional Application 61269432 · Jun 24, 2009
Related Publication 20110027235A1 · Feb 3, 2011